

Product datasheet for **KN420985**

SLAMF7 Human Gene Knockout Kit (CRISPR)

Product data:

| | |
|---------------|--|
| Product Type: | Knockout Kits (CRISPR) |
| Format: | 2 gRNA vectors, 1 linear donor |
| Donor DNA: | EF1a-GFP-P2A-Puro |
| Symbol: | SLAMF7 |
| Locus ID: | 57823 |
| Components: | <p>KN420985G1, SLAMF7 gRNA vector 1 in pCas-Guide CRISPR vector (GE100002), Target Sequence: GCTGCCAAAGGATATAGATG</p> <p>KN420985G2, SLAMF7 gRNA vector 2 in pCas-Guide CRISPR vector (GE100002), Target Sequence: GTCACCATACAGCCAGAAGG</p> <p>KN420985D, Linear donor DNA containing LoxP-EF1A-tGFP-P2A-Puro-LoxP: The sequence below is cassette sequence only. The linear donor DNA also contains proprietary target sequence.</p> |

LoxP-EF1A-tGFP-P2A-Puro-LoxP (2739 bp)

```

ATAACTTCGT ATAATGTATG CTATACGAAG TTATCGTGAG GCTCCGGTGC CCGTCAGTGG GCAGAGCGCA
CATCGCCAC AGTCCCCGAG AAGTTGGGGG GAGGGGTCCG CAATTGAACC GGTGCCTAGA GAAGGTGGCG
CGGGGTAAC TGGGAAAGTG ATGTCGTGTA CTGGCTCCGC CTTTTCCCG AGGGTGGGGG AGAACCATAT
ATAAGTGAC TAGTCGCCGT GAACGTTCTT TTTCCGAACG GGTTCGCCGC CAGAACACAG GTAAGTGCCG
TGTGTGGTTC CCGCGGGCCT GGCCTCTTTA CGGGTTATGG CCCTTGCGTG CCTTGAATTA CTCCACCTG
GCTGCAGTAC GTGATTCTTG ATCCCGAGCT TCGGGTTGGA AGTGGGTGGG AGAGTCCGAG GCCTTGCGCT
TAAGGAGCCC CTCGCCTCG TGCTTGAGTT GAGGCCTGCG CTGGGGCTG GGGCCCGCCG GTGCGAATCT
GGTGGCACCT TCGCGCCTGT CTCGCTGCTT TCGATAAGTC TCTAGCCATT TAAAATTTTT GATGACCTGC
TGCGACGCTT TTTTCTGGC AAGATAGTCT TGTAATGCG GGCCAAGATC TGCACACTGG TATTTTCGTT
TTTGGGGCCG CGGGCGGCGA CGGGGCCCGT GCGTCCCAGC GCACATGTTC GGCGAGGCGG GGCCTGCGAG
CGCGGCCACC GAGAATCGGA CGGGGGTAGT CTCAAGCTGG CCGGCCTGCT CTGGTGCCTG GCCTCGCGCC
GCCGTGTATC GCCCCGCCCT GGGCGGCAAG GCTGGCCCGG TCGGCACCAG TTGCGTGAGC GGAAAGATGG
CCGCTTCCCG GCCCTGCTGC AGGGAGCTCA AAATGGAGGA CGCGGCCTC GGGAGAGCGG GCGGGTGAGT
CACCCACACA AAGGAAAAGG GCCTTCCGT CTCAGCCGT CGTTTCATGT GACTCCACGG AGTACCGGGC
GCCGTCCAGG CACCTCGATT AGTTCTCGAG CTTTTGAGT ACGTCTGCTT TAGGTTGGGG GGAGGGGTTT
TATGCGATGG AGTTTCCCA CACTGAGTGG GTGGAGACTG AAGTTAGGCC AGCTTGCCAC TTGATGTAAT
TCTCCTTGA ATTTGCCCTT TTTGAGTTG GATCTTGGT CATTCTCAAG CCTCAGACAG TGGTTCAAAG
TTTTTTCTT CCATTTCAAG TGTCGTGAAT GGAGAGCGAC GAGAGCGGCC TGCCCGCCAT GGAGATCGAG
TGCCGCATCA CCGGCACCCT GAACGGCGTG GAGTTCGAGC TGGTGGGCGG CGGAGAGGGC ACCCCCAGC
AGGGCCGCAT GACCAACAAG ATGAAGAGCA CCAAAGGCGC CCTGACCTTC AGCCCCTACC TGCTGAGCCA
CGTGATGGG TACGGCTTCT ACCACTTCGG CACCTACCC AGCGGCTACG AGAACCCCTT CCTGCACGCC
ATCAACAACG GCGGCTACAC CAACACCCGC ATCGAGAAGT ACGAGGACGG CGGCGTGCT CACGTGAGCT
TCAGTACCG CTACGAGGCC GGCCCGTGGA TCGGCACACT CAAGGTGATG GGCACCGGCT TCCCCGAGGA
CAGCGTGATC TTCACCGACA AGATCATCCG CAGCAACGCC ACCGTGGAGC ACCTGCACCC CATGGGCGAT

```



```

AACGATCTGG ATGGCAGCTT CACCCGCACC TTCAGCCTGC GCGACGGCGG CTACTIONACAGC TCCGTGGTGG
ACAGCCACAT GCACTTCAAG AGCGCCATCC ACCCCAGCAT CCTGCAGAAC GGGGGCCCCA TGTTGCCTT
CCGCCCGGTG GAGGAGGATC ACAGCAACAC CGAGCTGGGC ATCGTGGAGT ACCAGCACGC CTTCAAGACC
CCGGATGCAG ATGCCGGTGA AGAAAGAGGA AGCGGAGCTA CTACTIONCAG CCTGCTGAAG CAGGCTGGAG
ACGTGGAGGA GAACCTGGA CCTATGACCG AGTACAAGCC CACGGTGGC CTCGCCACC GCGACGACGT
CCCCAGGGCC GTACGCACC TCGCCGCCG GTTCGCCGAC TACCCCGCCA CGGCCACAC CGTCGATCCG
GACCGCCACA TCGAGCGGGT CACCGAGCTG CAAGAACTCT TCCTCACGGC CGTCGGGCTC GATCGGGCA
AGGTGTGGGT CGCGGACGAC GCGCGCCGG TGGCGGTCTG GACCACGCCG GAGAGCGTCG AAGCGGGGC
GGTGTTCGCC GAGATCGGCC CGCGCATGGC CGAGTTGAGC GGTTCGCCG TGGCCGCGCA GCAACAGATG
GAAGGCCTCC TGGCGCCGCA CCGGCCAAG GAGCCCGCT GTTTCCTGGC CACCGTCGGC GTCTCGCCG
ACCACCAGGG CAAGGTCTG GGCAGCGCC TCGTGTCCC CGGAGTGGAG GCGGCCGAGC GCGCCGGGT
GCCCGCTTC CTGGAGACT CCGCGCCCG CAACCTCCC TTCTACGAGC GGCTCGGCTT CACCGTCACC
GCCGACGTC AGGTGCCGA AGGACCGCG ACCTGGTCA TGACCCGAA GCCCGGTGCC TGAAACTTGT
TTATTGCAGC TTATAATGGT TACAAATAA GCAATAGCAT CACAAATTC ACAAATAAG CATTITTTTC
ACTGCATTCT AGTTGTGGT TGTCCAACT CATCAATGTA TCTTAATAAC TTCGTATAAT GTATGCTATA CGAAGTTAT

```


Disclaimer:

These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.

RefSeq:

[NM_001282588](#), [NM_001282589](#), [NM_001282590](#), [NM_001282591](#), [NM_001282592](#),
[NM_001282593](#), [NM_001282594](#), [NM_001282595](#), [NM_001282596](#), [NM_021181](#)

UniProt ID:

[Q9NQ25](#)

Synonyms:

19A; CD319; CRACC; CS1

Summary:

Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform 1 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway (PubMed:11698418). Positively regulates NK cell functions by a mechanism dependent on phosphorylated SH2D1B. Downstream signaling implicates PLCG1, PLCG2 and PI3K (PubMed:16339536). In addition to heterotypic NK cells-target cells interactions also homotypic interactions between NK cells may contribute to activation. However, in the absence of SH2D1B, inhibits NK cell function. Acts also inhibitory in T-cells (By similarity). May play a role in lymphocyte adhesion (PubMed:11802771). In LPS-activated monocytes negatively regulates production of proinflammatory cytokines (PubMed:23695528).[UniProtKB/Swiss-Prot Function]

Product images:

